FDA 公布浙江国邦药业 483 观察报告,列 1 项水系统微生物控制观察
FDA 483:浙江国邦药业有限公司
FDA 公布浙江国邦药业有限公司(浙江上虞,FEI 3008617115)2025年3月3日签发的 483 观察报告,列 1 项水系统微生物控制观察。检查日期为2025年2月24日至28日及3月3日,观察指出微生物监测取样量未论证统计学有效,也未验证所取样品能否捕获更大体积样品中的全部菌落。
近日,FDA公布了浙江国邦药业有限公司(浙江省杭州湾上虞经济技术开发区纬五路6号,FEI 3008617115)的483观察报告,列1项观察,指向水系统的微生物控制。
包括:取样量太小、没论证统计学有效;生物膜释放的菌测不到,因为连正常菌群都没鉴定;质量标准里明明写着大肠埃希菌、铜绿假单胞菌、金黄色葡萄球菌不得检出,但 TAMC 和 TYMC 上长出来的菌,从来没做过菌种鉴定。
图1 FDA 483 原件第1页(FEI 3008617115,2025年3月3日签发)
Inspection Details
检查基本信息
Firm / 企业
Zhejiang Guobang Pharmaceutical Co., Ltd. 浙江国邦药业有限公司
Address / 地址
No. 6 Weiwu Road, Shaoxing, Zhejiang Province, 312300, P.R. China(浙江省杭州湾上虞经济技术开发区纬五路6号)
FEI Number / FEI 号
3008617115
Dates of Inspection / 检查日期
2025年2月24日–2月28日、3月3日(原件分两段记载)
Type Establishment Inspected / 受检设施类型
Active Pharmaceutical Ingredient Manufacturer(原料药生产企业)
Issued To / 收件人
Mr. Yao Ligao, Director of the Board(姚礼高,执行董事)
District Office / 地区办公室
12420 Parklawn, Room 2032, Rockville, MD 20857(回复邮箱同时给了 CDER 与 CVM 两套)
Issued / 签发
2025年3月3日 检查员:Monica E. Murie;Victoria Spivak
说明:原件未印法规条款号。本项观察的标题为 21 CFR 211.160(b) 的改写,属编者对应,见文末译注①。
OBSERVATION 1
观察1:实验室控制(编者对应 21 CFR 211.160(b))
Laboratory controls lack scientifically justified and appropriate specifications and test procedures necessary to ensure that components meet established standards for identity, quality, and purity.
实验室控制缺乏科学合理且适当的质量标准与检测方法,以确保组分符合既定的鉴别、质量、纯度标准。
Specifically, (b)(4) water is utilized in the critical cleaning of equipment in classified rooms during the manufacturing processes of your drug substances. (b)(4) water was also used as a component in the manufacturing of drug substances including, but not limited to, (b)(4) Batch (b)(4) released and shipped to the US market.
具体而言,(b)(4) 水用于原料药生产过程中洁净区内设备的关键清洁。(b)(4) 水也作为组分用于原料药生产,包括但不限于 (b)(4) 批次 (b)(4),已放行并发往美国市场。
A. USP compendial methods recognize that scientific standards for culturing (b)(4) water samples include sample sizes of up to (b)(4) mL for (b)(4). Your firm has not justified that the (b)(4) mL sample of (b)(4) water currently tested for microbial monitoring of (b)(4) sampling locations is appropriate to derive statistically valid colony counts at your site. Additionally, your firm has not validated that the (b)(4) mL sample taken for (b)(4) adequately captures all microbial colonies present in the larger (b)(4) mL sample collected at each (b)(4) water (b)(4).
A. 美国药典的方法承认,培养 (b)(4) 水样的科学标准包括取样量可达 (b)(4) mL,用于 (b)(4)。贵公司未论证:目前对 (b)(4) 个取样点做微生物监测所用的 (b)(4) mL (b)(4) 水样,足以在贵公司现场得出统计学上有效的菌落计数。此外,贵公司未验证:所取的 (b)(4) mL 样品,足以捕获每个 (b)(4) 水 (b)(4) 所采集的更大体积 (b)(4) mL 样品中存在的所有微生物菌落。
B. Your firm has failed to detect and enumerate microorganisms that have been released by potential biofilms within your (b)(4) water system to evaluate the overall state of control of the (b)(4) water system. Current method validation studies do not include additional organisms typically isolated from the (b)(4) water system (house isolates) since your firm does not identify the normal microbiome.
B. 贵公司未能检测并计数可能由生物膜释放到 (b)(4) 水系统中的微生物,因而无法评估该 (b)(4) 水系统的整体控制状态。现行方法验证研究未纳入通常从 (b)(4) 水系统分离到的其他微生物(本厂分离株),原因是贵公司未鉴定正常微生物群。
C. Your firm's (b)(4) water specification is not scientifically justified to exclude objectionable microorganisms from the (b)(4) water samples cultured during the tests for Total Aerobic Microbial Count (TAMC) and Total Yeast and Molds Count (TYMC). The microbial specifications for (b)(4) water include "Total Viable Bacteria Count <=(b)(4) cfu/mL", "Total Aerobic Microbial Count <=(b)(4) cfu/mL", "Total Bacteria, Molds and Yeasts Count <=(b)(4) cfu/mL", and "Specified Microorganisms: Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus should be (b)(4) per (b)(4) mL of water sample". Your firm has failed to speciate recoveries found on TAMC and TYMC (b)(4) to determine if the specified objectionable microorganisms or other pathogenic bacteria are present in your (b)(4) water system below alert and action limits.
C. 贵公司 (b)(4) 水的质量标准,在科学上不足以排除 (b)(4) 水样中的不可接受微生物——这些水样取自总需氧菌数(TAMC)与总酵母和霉菌数(TYMC)检测。该 (b)(4) 水的微生物标准包括“总活菌数 <=(b)(4) cfu/mL”“总需氧菌数 <=(b)(4) cfu/mL”“总细菌、霉菌和酵母数 <=(b)(4) cfu/mL”,以及“指定微生物:大肠埃希菌、铜绿假单胞菌和金黄色葡萄球菌,应为每 (b)(4) mL 水样 (b)(4)”。贵公司未对 TAMC 与 TYMC (b)(4) 上长出的菌落做菌种鉴定,因而无法判断在警戒限与纠偏限以下,该 (b)(4) 水系统中是否存在指定微生物或其他致病菌。
图2 原件第2页:C 项续文与两位检查员的签字
来源:制药经理人 · mp.weixin.qq.com